AQST on XNAS, Health Care, Aquestive Therapeutics, Inc., job postings
Measures activity, not value. Not investment advice.
Quarterly revenue fell 41% to $7.6M while short interest stands at 23% of shares.
BadNet loss $79.3M over 12 months and free cash outflow $40.7M
BadShares down 38% over the last 12 months
Written by AI from the data on this page, 22 Nov 2026. Not investment advice.
Profile and fundamentals
From its SEC filings, 12 months to 30 Sep 2026
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif, and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.
expected around 3 Mar 2027 (an estimate: a year ago it reported on 4 Mar 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $7.6M, net loss $16.5M.
31 Dec 2021RevenueNet incomeNet losstallest bar $31.9M30 Sep 2026
See the numbers
Quarter to
Revenue
Net income
30 Sep 2026
$7.6M
-$16.5M
30 Jun 2026
$13.8M
-$22.9M
31 Mar 2026
$14.4M
-$8.1M
31 Dec 2025
$13.0M
-$31.9M
30 Sep 2025
$12.8M
-$15.4M
30 Jun 2025
$10.0M
-$13.5M
31 Mar 2025
$8.7M
-$22.9M
31 Dec 2024
$11.9M
-$17.1M
30 Sep 2024
$13.5M
-$11.5M
30 Jun 2024
$20.1M
-$2.7M
31 Mar 2024
$12.1M
-$12.8M
31 Dec 2023
$13.2M
-$8.1M
30 Sep 2023
$13.0M
-$2.0M
30 Jun 2023
$13.2M
-$5.8M
31 Mar 2023
$11.1M
$8.1M
31 Dec 2022
$10.7M
-$12.4M
30 Sep 2022
$11.5M
-$12.5M
30 Jun 2022
$13.3M
-$16.3M
31 Mar 2022
$12.3M
-$13.2M
31 Dec 2021
$11.1M
-$28.9M
Fundamentals, 12 months to 30 Sep 2026
Measure
Latest
Year before
Peer median
RevenueiSales over the last 12 months reported.
$48.8M
$43.4M
Revenue growthiRevenue of the last 12 months compared with the 12 months before.
+13%
+11%
Net incomeiProfit after all costs and taxes over the last 12 months reported. Negative is a loss.
-$79.3M
-$69.0M
EPS (diluted)iEarnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split).
-$0.65
-$0.71
Gross marginiWhat is left of each dollar of sales after the direct cost of making the product or service.
65.3%
60.3%
73.2%
Operating marginiOperating income as a share of sales: profit from the business before interest and taxes.
-114%
-129%
-25.0%
Net marginiNet income as a share of sales: what the owners keep of each dollar sold.
-162%
-159%
-18.2%
Return on equityiNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money.
–
-58.8%
Free cash flowiCash from operations minus capital spending over the last 12 months: cash the business produced.
-$40.7M
-$50.9M
CashiCash, cash equivalents and short-term investments on the latest balance sheet.
$90.3M
$129.1M
DebtiShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted.
$50.8M
$45.0M
Net debtiDebt minus cash. Negative means the company holds more cash than it owes (net cash).
-$39.6M (net cash)
-$84.1M
Debt to equityiDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative.
–
0.0
Book value per shareiShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding.
–
P/EiPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss.
loss
19.3
P/SiPrice to sales: market cap divided by revenue of the last 12 months.
8.9
5.0
EV/SalesiEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months.
8.1
5.0
P/BiPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative.
–
2.0
Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.
Peers nearest by market cap, its own industry first
Insider Buy/Sell iShares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.
-$198K
bought $99K, sold $297K
Institutional holders iThe number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.
+2.7%
188 13F filers vs 183
Institutional ownership iShares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.
60%
75.6M shares held by 13F filers (30 Sep 2026) of 125.7M outstanding (30 Oct 2026)
Short interest iShares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.
23%
29.3M shares sold short (30 Oct 2026) of 125.7M outstanding (30 Oct 2026)
Days to cover iShort interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.
13.2
29.3M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it
Short interest change iHow the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.
+6.2%
27.6M shares sold short in the report before, 29.3M on 30 Oct 2026
Short sale volume iShare of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.
68%
68% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 50%
Open jobs iJob postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.
–
We do not track this company's careers site yet.
Open jobs change iHow the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.
–
We do not track this company's careers site yet.
Employees iTotal staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.
–
No headcount in its annual reports in our data.
Visa hiring (foreign workers) iApplications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.
–
No data for this company
Revenue growth iSales in the latest reported quarter compared with the same quarter a year earlier.
-41%
$7.6M vs $12.8M (quarter ended 30 Sep 2026)
Capital spending iMoney spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.
–
No data for this company
Federal contracts iMoney the US government committed to the company in contracts and grants over the last 12 months.
–
No data for this company
Lobbying iWhat the company reported spending on federal lobbying over the last four quarters.
$240K
4 quarters, $
Layoff notices iWorkers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).
–
No data for this company
News (7d) iArticles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.
14
14 articles in the last 7 days; its usual week has 1 (the median of the 26 weeks before).
News vs usual iArticles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.
14×
14 articles in the last 7 days; its usual week has 1.
Unusual now sharp changes in the last 90 days, compared with its own past
Revenue $7.6M, -41% vs a year earlier
Price $3.46 on 20 Nov 2026, -38% over 12 months (12-month range $2.95 to $6.62)
Sharp change
8-K and other filings
Lobbying filing
Insider net buying (open market). Insiders sold a net $2.3M in the last 12 months (the 12 months before: -$1.7M).Revenue per quarter. Revenue $7.6M in the latest quarter, -41% on a year earlier.Capital spending per quarter. Capital spending $584K in the latest quarter, +149% on a year earlier.Institutional holders (13F filers). 188 13F filers reported holding it in the latest 13F quarter, +31% on a year earlier.Lobbying spend. Lobbying spend: $240K published in the last 12 months, +140% on the 12 months before.
Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: h-1b/e-3 applications certified, federal obligations, workers in warn layoff notices.
Reported lobbying spend: $60K in Q3 2026, $60K in Q2 2026. Rows are lobbying firms hired or let go; amounts are reported per quarter, not per firm here.
Date
Change
Lobbying firm
Issue
Source
1 Jul 2025
New
Bracewell LLPfor Aquestive Therapeutics
Issues related to Poison Prevention Packaging ActConsumer safety
Two or more unrelated kinds of records unusual within 30 days
18 Nov 2025confirmed
Confirmed across sources Lobbying and Short interest and volume
Aquestive Therapeutics(AQST): lobbying on a new issue, while it had 24.1M shares sold short in the 31 Dec 2025 report, 2.3× the same report last year. Two unrelated kinds of activity within 134 days.
Lobbying: Lobbying on a new issue, became public on 20 Oct 2025
Short interest and volume: Short interest spike, became public on 13 Nov 2025
Short interest and volume: Short interest spike, became public on 26 Nov 2025
Short interest and volume: Short interest spike, became public on 10 Dec 2025
Short interest and volume: Short interest spike, became public on 25 Dec 2025
Short interest and volume: Short interest spike, became public on 13 Jan 2026
Short interest and volume: Short interest spike, became public on 28 Jan 2026
Short interest and volume: Short interest spike, became public on 11 Feb 2026
Short interest and volume: Short interest spike, became public on 26 Feb 2026
The 31 Dec 2025 report against the 24 reports before it.
this reportearliernormal: 10.4MSee the evidence (9 changes)
Lobbying: Lobbying on a new issue became public on 20 Oct 2025
Aquestive Therapeutics lobbying on a new issue.
New
['CSP']
Rule
only points whose every posting (and value revision) is at or before as_of
Field
issue_codes
Metric
lobbying.filings_count
Point id
4690060
Short interest and volume: Short interest spike became public on 13 Nov 2025
Aquestive Therapeutics had 14.7M shares sold short in the 31 Oct 2025 report, 1.5× the same report last year.
This period
14.7M (the 31 Oct 2025 report)
Normal report (median of 24 earlier)
10.0M
Typical spread (median absolute deviation)
521K
How far from its usual level
+4.7
Same report last year
10.1M
History used
2,649 days
the 31 Oct 2025 report24 earlier reportsnormal: 10.0M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 26 Nov 2025
Aquestive Therapeutics had 19.2M shares sold short in the 14 Nov 2025 report, 1.9× the same report last year.
This period
19.2M (the 14 Nov 2025 report)
Normal report (median of 24 earlier)
10.0M
Typical spread (median absolute deviation)
590K
How far from its usual level
+9.2
Same report last year
10.0M
History used
2,663 days
the 14 Nov 2025 report24 earlier reportsnormal: 10.0M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 10 Dec 2025
Aquestive Therapeutics had 19.8M shares sold short in the 28 Nov 2025 report, 2.0× the same report last year.
This period
19.8M (the 28 Nov 2025 report)
Normal report (median of 24 earlier)
10.1M
Typical spread (median absolute deviation)
745K
How far from its usual level
+8.8
Same report last year
10.2M
History used
2,677 days
the 28 Nov 2025 report24 earlier reportsnormal: 10.1M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 25 Dec 2025
Aquestive Therapeutics had 21.9M shares sold short in the 15 Dec 2025 report, 2.3× the same report last year.
This period
21.9M (the 15 Dec 2025 report)
Normal report (median of 24 earlier)
10.1M
Typical spread (median absolute deviation)
906K
How far from its usual level
+8.8
Same report last year
9.7M
History used
2,694 days
the 15 Dec 2025 report24 earlier reportsnormal: 10.1M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 13 Jan 2026
Aquestive Therapeutics had 24.1M shares sold short in the 31 Dec 2025 report, 2.3× the same report last year.
This period
24.1M (the 31 Dec 2025 report)
Normal report (median of 24 earlier)
10.4M
Typical spread (median absolute deviation)
931K
How far from its usual level
+10.0
Same report last year
10.5M
History used
2,710 days
the 31 Dec 2025 report24 earlier reportsnormal: 10.4M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 28 Jan 2026
Aquestive Therapeutics had 20.3M shares sold short in the 15 Jan 2026 report, 1.7× the same report last year.
This period
20.3M (the 15 Jan 2026 report)
Normal report (median of 24 earlier)
10.7M
Typical spread (median absolute deviation)
1.2M
How far from its usual level
+5.5
Same report last year
11.8M
History used
2,725 days
the 15 Jan 2026 report24 earlier reportsnormal: 10.7M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 11 Feb 2026
Aquestive Therapeutics had 20.4M shares sold short in the 30 Jan 2026 report, 1.8× the same report last year.
This period
20.4M (the 30 Jan 2026 report)
Normal report (median of 24 earlier)
10.7M
Typical spread (median absolute deviation)
1.2M
How far from its usual level
+5.3
Same report last year
11.1M
History used
2,740 days
the 30 Jan 2026 report24 earlier reportsnormal: 10.7M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 26 Feb 2026
Aquestive Therapeutics had 20.0M shares sold short in the 13 Feb 2026 report, 2.0× the same report last year.
This period
20.0M (the 13 Feb 2026 report)
Normal report (median of 24 earlier)
10.7M
Typical spread (median absolute deviation)
1.3M
How far from its usual level
+4.9
Same report last year
10.0M
History used
2,754 days
the 13 Feb 2026 report24 earlier reportsnormal: 10.7M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
21 May 2024confirmed
Confirmed across sources Institutional holdings and Filings + Financials and Short interest and volume
Aquestive Therapeutics(AQST): saw 47 13F filers open a new position in the quarter ended 31 Mar 2024, 9.4× the same quarter last year; it also reported revenue of $20.1M for the quarter ended 30 Jun 2024, 1.5× the same quarter last year; and it had 11.1M shares sold short in the 30 Sep 2024 report, 5.4× the same report last year. Three unrelated kinds of activity within 182 days.
Short interest and volume: Short interest spike, became public on 25 Apr 2024
Short interest and volume: Short interest spike, became public on 10 May 2024
Institutional holdings: Many funds opening a new position, became public on 15 May 2024
Short interest and volume: Short interest spike, became public on 25 May 2024
Short interest and volume: Short interest spike, became public on 12 Jun 2024
Short interest and volume: Short interest spike, became public on 27 Jun 2024
Short interest and volume: Short interest spike, became public on 11 Jul 2024
Short interest and volume: Short interest spike, became public on 25 Jul 2024
Financials: Quarterly revenue change, became public on 13 Aug 2024
Short interest and volume: Short interest spike, became public on 10 Aug 2024
Short interest and volume: Short interest spike, became public on 27 Aug 2024
Short interest and volume: Short interest spike, became public on 12 Sep 2024
Short interest and volume: Short interest spike, became public on 25 Sep 2024
Short interest and volume: Short interest spike, became public on 10 Oct 2024
Short interest and volume: Short interest spike, became public on 25 Oct 2024
The quarter ended 31 Mar 2024 against the 8 quarters before it.
this quarterearliernormal: 5See the evidence (15 changes)
Short interest and volume: Short interest spike became public on 25 Apr 2024
Aquestive Therapeutics had 4.0M shares sold short in the 15 Apr 2024 report, 2.1× the same report last year.
This period
4.0M (the 15 Apr 2024 report)
Normal report (median of 24 earlier)
1.9M
Typical spread (median absolute deviation)
92K
How far from its usual level
+10.6
Same report last year
1.9M
History used
2,085 days
the 15 Apr 2024 report24 earlier reportsnormal: 1.9M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 10 May 2024
Aquestive Therapeutics had 5.3M shares sold short in the 30 Apr 2024 report, 2.9× the same report last year.
This period
5.3M (the 30 Apr 2024 report)
Normal report (median of 24 earlier)
2.0M
Typical spread (median absolute deviation)
95K
How far from its usual level
+17.0
Same report last year
1.8M
History used
2,100 days
the 30 Apr 2024 report24 earlier reportsnormal: 2.0M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Institutional holdings: Many funds opening a new position became public on 15 May 2024
Aquestive Therapeutics saw 47 13F filers open a new position in the quarter ended 31 Mar 2024, 9.4× the same quarter last year.
This period
47 (the quarter ended 31 Mar 2024)
Normal quarter (median of 8 earlier)
5
Typical spread (median absolute deviation)
2
How far from its usual level
+14.0
Same quarter last year
5
History used
2,009 days
the quarter ended 31 Mar 20248 earlier quartersnormal: 5
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
Short interest and volume: Short interest spike became public on 25 May 2024
Aquestive Therapeutics had 6.2M shares sold short in the 15 May 2024 report, 3.2× the same report last year.
This period
6.2M (the 15 May 2024 report)
Normal report (median of 24 earlier)
2.0M
Typical spread (median absolute deviation)
90K
How far from its usual level
+21.6
Same report last year
1.9M
History used
2,115 days
the 15 May 2024 report24 earlier reportsnormal: 2.0M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 12 Jun 2024
Aquestive Therapeutics had 6.7M shares sold short in the 31 May 2024 report, 3.4× the same report last year.
This period
6.7M (the 31 May 2024 report)
Normal report (median of 24 earlier)
2.0M
Typical spread (median absolute deviation)
96K
How far from its usual level
+24.0
Same report last year
2.0M
History used
2,131 days
the 31 May 2024 report24 earlier reportsnormal: 2.0M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 27 Jun 2024
Aquestive Therapeutics had 7.2M shares sold short in the 14 Jun 2024 report, 3.2× the same report last year.
This period
7.2M (the 14 Jun 2024 report)
Normal report (median of 24 earlier)
2.0M
Typical spread (median absolute deviation)
123K
How far from its usual level
+26.1
Same report last year
2.2M
History used
2,145 days
the 14 Jun 2024 report24 earlier reportsnormal: 2.0M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 11 Jul 2024
Aquestive Therapeutics had 7.6M shares sold short in the 28 Jun 2024 report, 4.4× the same report last year.
This period
7.6M (the 28 Jun 2024 report)
Normal report (median of 24 earlier)
2.0M
Typical spread (median absolute deviation)
123K
How far from its usual level
+28.4
Same report last year
1.7M
History used
2,159 days
the 28 Jun 2024 report24 earlier reportsnormal: 2.0M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 25 Jul 2024
Aquestive Therapeutics had 10.4M shares sold short in the 15 Jul 2024 report, 5.4× the same report last year.
This period
10.4M (the 15 Jul 2024 report)
Normal report (median of 24 earlier)
2.0M
Typical spread (median absolute deviation)
147K
How far from its usual level
+38.3
Same report last year
1.9M
History used
2,176 days
the 15 Jul 2024 report24 earlier reportsnormal: 2.0M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Financials: Quarterly revenue change became public on 13 Aug 2024
Aquestive Therapeutics reported revenue of $20.1M for the quarter ended 30 Jun 2024, 1.5× the same quarter last year.
This period
$20.1M (the quarter ended 30 Jun 2024)
Normal quarter (median of 8 earlier)
$12.5M
Typical spread (median absolute deviation)
$726K
How far from its usual level
+6.0
Same quarter last year
$13.2M
History used
2,648 days
the quarter ended 30 Jun 20248 earlier quartersnormal: $12.5M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
Short interest and volume: Short interest spike became public on 10 Aug 2024
Aquestive Therapeutics had 10.8M shares sold short in the 31 Jul 2024 report, 5.3× the same report last year.
This period
10.8M (the 31 Jul 2024 report)
Normal report (median of 24 earlier)
2.0M
Typical spread (median absolute deviation)
205K
How far from its usual level
+28.8
Same report last year
2.0M
History used
2,192 days
the 31 Jul 2024 report24 earlier reportsnormal: 2.0M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 27 Aug 2024
Aquestive Therapeutics had 10.8M shares sold short in the 15 Aug 2024 report, 5.5× the same report last year.
This period
10.8M (the 15 Aug 2024 report)
Normal report (median of 24 earlier)
2.0M
Typical spread (median absolute deviation)
226K
How far from its usual level
+26.1
Same report last year
2.0M
History used
2,207 days
the 15 Aug 2024 report24 earlier reportsnormal: 2.0M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 12 Sep 2024
Aquestive Therapeutics had 10.8M shares sold short in the 30 Aug 2024 report, 5.9× the same report last year.
This period
10.8M (the 30 Aug 2024 report)
Normal report (median of 24 earlier)
2.1M
Typical spread (median absolute deviation)
244K
How far from its usual level
+24.2
Same report last year
1.8M
History used
2,222 days
the 30 Aug 2024 report24 earlier reportsnormal: 2.1M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 25 Sep 2024
Aquestive Therapeutics had 10.8M shares sold short in the 13 Sep 2024 report, 5.8× the same report last year.
This period
10.8M (the 13 Sep 2024 report)
Normal report (median of 24 earlier)
2.2M
Typical spread (median absolute deviation)
340K
How far from its usual level
+17.1
Same report last year
1.8M
History used
2,236 days
the 13 Sep 2024 report24 earlier reportsnormal: 2.2M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 10 Oct 2024
Aquestive Therapeutics had 11.1M shares sold short in the 30 Sep 2024 report, 5.4× the same report last year.
This period
11.1M (the 30 Sep 2024 report)
Normal report (median of 24 earlier)
2.3M
Typical spread (median absolute deviation)
520K
How far from its usual level
+11.4
Same report last year
2.0M
History used
2,253 days
the 30 Sep 2024 report24 earlier reportsnormal: 2.3M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 25 Oct 2024
Aquestive Therapeutics had 10.8M shares sold short in the 15 Oct 2024 report, 5.4× the same report last year.
This period
10.8M (the 15 Oct 2024 report)
Normal report (median of 24 earlier)
3.2M
Typical spread (median absolute deviation)
1.4M
How far from its usual level
+3.7
Same report last year
2.0M
History used
2,268 days
the 15 Oct 2024 report24 earlier reportsnormal: 3.2M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
Timeline
Changes and notable records, by the date each became public
reported revenue of $7.6M for the quarter ended 30 Sep 2026, 41% below the same quarter last year.
Same quarter last year: $12.8M; its normal quarter is $12.9M.
See the evidence
This period
$7.6M (the quarter ended 30 Sep 2026)
Normal quarter (median of 8 earlier)
$12.9M
Typical spread (median absolute deviation)
$976K
How far from its usual level
-3.7
Same quarter last year
$12.8M
History used
3,470 days
the quarter ended 30 Sep 20268 earlier quartersnormal: $12.9M
Fires when the period is at least 3.0 robust standard deviations away from the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
had 20.0M shares sold short in the 13 Feb 2026 report, 2.0× the same report last year.
Same report last year: 10.0M; its normal report is 10.7M.
See the evidence
This period
20.0M (the 13 Feb 2026 report)
Normal report (median of 24 earlier)
10.7M
Typical spread (median absolute deviation)
1.3M
How far from its usual level
+4.9
Same report last year
10.0M
History used
2,754 days
the 13 Feb 2026 report24 earlier reportsnormal: 10.7M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 20.4M shares sold short in the 30 Jan 2026 report, 1.8× the same report last year.
Same report last year: 11.1M; its normal report is 10.7M.
See the evidence
This period
20.4M (the 30 Jan 2026 report)
Normal report (median of 24 earlier)
10.7M
Typical spread (median absolute deviation)
1.2M
How far from its usual level
+5.3
Same report last year
11.1M
History used
2,740 days
the 30 Jan 2026 report24 earlier reportsnormal: 10.7M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 20.3M shares sold short in the 15 Jan 2026 report, 1.7× the same report last year.
Same report last year: 11.8M; its normal report is 10.7M.
See the evidence
This period
20.3M (the 15 Jan 2026 report)
Normal report (median of 24 earlier)
10.7M
Typical spread (median absolute deviation)
1.2M
How far from its usual level
+5.5
Same report last year
11.8M
History used
2,725 days
the 15 Jan 2026 report24 earlier reportsnormal: 10.7M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 24.1M shares sold short in the 31 Dec 2025 report, 2.3× the same report last year.
Same report last year: 10.5M; its normal report is 10.4M.
See the evidence
This period
24.1M (the 31 Dec 2025 report)
Normal report (median of 24 earlier)
10.4M
Typical spread (median absolute deviation)
931K
How far from its usual level
+10.0
Same report last year
10.5M
History used
2,710 days
the 31 Dec 2025 report24 earlier reportsnormal: 10.4M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 21.9M shares sold short in the 15 Dec 2025 report, 2.3× the same report last year.
Same report last year: 9.7M; its normal report is 10.1M.
See the evidence
This period
21.9M (the 15 Dec 2025 report)
Normal report (median of 24 earlier)
10.1M
Typical spread (median absolute deviation)
906K
How far from its usual level
+8.8
Same report last year
9.7M
History used
2,694 days
the 15 Dec 2025 report24 earlier reportsnormal: 10.1M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 19.8M shares sold short in the 28 Nov 2025 report, 2.0× the same report last year.
Same report last year: 10.2M; its normal report is 10.1M.
See the evidence
This period
19.8M (the 28 Nov 2025 report)
Normal report (median of 24 earlier)
10.1M
Typical spread (median absolute deviation)
745K
How far from its usual level
+8.8
Same report last year
10.2M
History used
2,677 days
the 28 Nov 2025 report24 earlier reportsnormal: 10.1M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 19.2M shares sold short in the 14 Nov 2025 report, 1.9× the same report last year.
Same report last year: 10.0M; its normal report is 10.0M.
See the evidence
This period
19.2M (the 14 Nov 2025 report)
Normal report (median of 24 earlier)
10.0M
Typical spread (median absolute deviation)
590K
How far from its usual level
+9.2
Same report last year
10.0M
History used
2,663 days
the 14 Nov 2025 report24 earlier reportsnormal: 10.0M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
lobbying on a new issue, while it had 24.1M shares sold short in the 31 Dec 2025 report, 2.3× the same report last year. Two unrelated kinds of activity within 134 days.
See the evidence (9 changes)
Lobbying: Lobbying on a new issue became public on 20 Oct 2025
Aquestive Therapeutics lobbying on a new issue.
New
['CSP']
Rule
only points whose every posting (and value revision) is at or before as_of
Field
issue_codes
Metric
lobbying.filings_count
Point id
4690060
Short interest and volume: Short interest spike became public on 13 Nov 2025
Aquestive Therapeutics had 14.7M shares sold short in the 31 Oct 2025 report, 1.5× the same report last year.
This period
14.7M (the 31 Oct 2025 report)
Normal report (median of 24 earlier)
10.0M
Typical spread (median absolute deviation)
521K
How far from its usual level
+4.7
Same report last year
10.1M
History used
2,649 days
the 31 Oct 2025 report24 earlier reportsnormal: 10.0M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 26 Nov 2025
Aquestive Therapeutics had 19.2M shares sold short in the 14 Nov 2025 report, 1.9× the same report last year.
This period
19.2M (the 14 Nov 2025 report)
Normal report (median of 24 earlier)
10.0M
Typical spread (median absolute deviation)
590K
How far from its usual level
+9.2
Same report last year
10.0M
History used
2,663 days
the 14 Nov 2025 report24 earlier reportsnormal: 10.0M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 10 Dec 2025
Aquestive Therapeutics had 19.8M shares sold short in the 28 Nov 2025 report, 2.0× the same report last year.
This period
19.8M (the 28 Nov 2025 report)
Normal report (median of 24 earlier)
10.1M
Typical spread (median absolute deviation)
745K
How far from its usual level
+8.8
Same report last year
10.2M
History used
2,677 days
the 28 Nov 2025 report24 earlier reportsnormal: 10.1M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 25 Dec 2025
Aquestive Therapeutics had 21.9M shares sold short in the 15 Dec 2025 report, 2.3× the same report last year.
This period
21.9M (the 15 Dec 2025 report)
Normal report (median of 24 earlier)
10.1M
Typical spread (median absolute deviation)
906K
How far from its usual level
+8.8
Same report last year
9.7M
History used
2,694 days
the 15 Dec 2025 report24 earlier reportsnormal: 10.1M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 13 Jan 2026
Aquestive Therapeutics had 24.1M shares sold short in the 31 Dec 2025 report, 2.3× the same report last year.
This period
24.1M (the 31 Dec 2025 report)
Normal report (median of 24 earlier)
10.4M
Typical spread (median absolute deviation)
931K
How far from its usual level
+10.0
Same report last year
10.5M
History used
2,710 days
the 31 Dec 2025 report24 earlier reportsnormal: 10.4M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 28 Jan 2026
Aquestive Therapeutics had 20.3M shares sold short in the 15 Jan 2026 report, 1.7× the same report last year.
This period
20.3M (the 15 Jan 2026 report)
Normal report (median of 24 earlier)
10.7M
Typical spread (median absolute deviation)
1.2M
How far from its usual level
+5.5
Same report last year
11.8M
History used
2,725 days
the 15 Jan 2026 report24 earlier reportsnormal: 10.7M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 11 Feb 2026
Aquestive Therapeutics had 20.4M shares sold short in the 30 Jan 2026 report, 1.8× the same report last year.
This period
20.4M (the 30 Jan 2026 report)
Normal report (median of 24 earlier)
10.7M
Typical spread (median absolute deviation)
1.2M
How far from its usual level
+5.3
Same report last year
11.1M
History used
2,740 days
the 30 Jan 2026 report24 earlier reportsnormal: 10.7M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 26 Feb 2026
Aquestive Therapeutics had 20.0M shares sold short in the 13 Feb 2026 report, 2.0× the same report last year.
This period
20.0M (the 13 Feb 2026 report)
Normal report (median of 24 earlier)
10.7M
Typical spread (median absolute deviation)
1.3M
How far from its usual level
+4.9
Same report last year
10.0M
History used
2,754 days
the 13 Feb 2026 report24 earlier reportsnormal: 10.7M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
13 Nov 2025Short interest and volume change
had 14.7M shares sold short in the 31 Oct 2025 report, 1.5× the same report last year.
Same report last year: 10.1M; its normal report is 10.0M.
See the evidence
This period
14.7M (the 31 Oct 2025 report)
Normal report (median of 24 earlier)
10.0M
Typical spread (median absolute deviation)
521K
How far from its usual level
+4.7
Same report last year
10.1M
History used
2,649 days
the 31 Oct 2025 report24 earlier reportsnormal: 10.0M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
reported revenue of $8.7M for the quarter ended 31 Mar 2025, 28% below the same quarter last year.
Same quarter last year: $12.1M; its normal quarter is $13.1M.
See the evidence
This period
$8.7M (the quarter ended 31 Mar 2025)
Normal quarter (median of 8 earlier)
$13.1M
Typical spread (median absolute deviation)
$744K
How far from its usual level
-3.3
Same quarter last year
$12.1M
History used
2,922 days
the quarter ended 31 Mar 20258 earlier quartersnormal: $13.1M
Fires when the period is at least 3.0 robust standard deviations away from the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
had 10.8M shares sold short in the 15 Oct 2024 report, 5.4× the same report last year.
Same report last year: 2.0M; its normal report is 3.2M.
See the evidence
This period
10.8M (the 15 Oct 2024 report)
Normal report (median of 24 earlier)
3.2M
Typical spread (median absolute deviation)
1.4M
How far from its usual level
+3.7
Same report last year
2.0M
History used
2,268 days
the 15 Oct 2024 report24 earlier reportsnormal: 3.2M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 11.1M shares sold short in the 30 Sep 2024 report, 5.4× the same report last year.
Same report last year: 2.0M; its normal report is 2.3M.
See the evidence
This period
11.1M (the 30 Sep 2024 report)
Normal report (median of 24 earlier)
2.3M
Typical spread (median absolute deviation)
520K
How far from its usual level
+11.4
Same report last year
2.0M
History used
2,253 days
the 30 Sep 2024 report24 earlier reportsnormal: 2.3M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 10.8M shares sold short in the 13 Sep 2024 report, 5.8× the same report last year.
Same report last year: 1.8M; its normal report is 2.2M.
See the evidence
This period
10.8M (the 13 Sep 2024 report)
Normal report (median of 24 earlier)
2.2M
Typical spread (median absolute deviation)
340K
How far from its usual level
+17.1
Same report last year
1.8M
History used
2,236 days
the 13 Sep 2024 report24 earlier reportsnormal: 2.2M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 10.8M shares sold short in the 30 Aug 2024 report, 5.9× the same report last year.
Same report last year: 1.8M; its normal report is 2.1M.
See the evidence
This period
10.8M (the 30 Aug 2024 report)
Normal report (median of 24 earlier)
2.1M
Typical spread (median absolute deviation)
244K
How far from its usual level
+24.2
Same report last year
1.8M
History used
2,222 days
the 30 Aug 2024 report24 earlier reportsnormal: 2.1M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 10.8M shares sold short in the 15 Aug 2024 report, 5.5× the same report last year.
Same report last year: 2.0M; its normal report is 2.0M.
See the evidence
This period
10.8M (the 15 Aug 2024 report)
Normal report (median of 24 earlier)
2.0M
Typical spread (median absolute deviation)
226K
How far from its usual level
+26.1
Same report last year
2.0M
History used
2,207 days
the 15 Aug 2024 report24 earlier reportsnormal: 2.0M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
reported revenue of $20.1M for the quarter ended 30 Jun 2024, 1.5× the same quarter last year.
Same quarter last year: $13.2M; its normal quarter is $12.5M.
See the evidence
This period
$20.1M (the quarter ended 30 Jun 2024)
Normal quarter (median of 8 earlier)
$12.5M
Typical spread (median absolute deviation)
$726K
How far from its usual level
+6.0
Same quarter last year
$13.2M
History used
2,648 days
the quarter ended 30 Jun 20248 earlier quartersnormal: $12.5M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
had 10.8M shares sold short in the 31 Jul 2024 report, 5.3× the same report last year.
Same report last year: 2.0M; its normal report is 2.0M.
See the evidence
This period
10.8M (the 31 Jul 2024 report)
Normal report (median of 24 earlier)
2.0M
Typical spread (median absolute deviation)
205K
How far from its usual level
+28.8
Same report last year
2.0M
History used
2,192 days
the 31 Jul 2024 report24 earlier reportsnormal: 2.0M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 10.4M shares sold short in the 15 Jul 2024 report, 5.4× the same report last year.
Same report last year: 1.9M; its normal report is 2.0M.
See the evidence
This period
10.4M (the 15 Jul 2024 report)
Normal report (median of 24 earlier)
2.0M
Typical spread (median absolute deviation)
147K
How far from its usual level
+38.3
Same report last year
1.9M
History used
2,176 days
the 15 Jul 2024 report24 earlier reportsnormal: 2.0M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 7.6M shares sold short in the 28 Jun 2024 report, 4.4× the same report last year.
Same report last year: 1.7M; its normal report is 2.0M.
See the evidence
This period
7.6M (the 28 Jun 2024 report)
Normal report (median of 24 earlier)
2.0M
Typical spread (median absolute deviation)
123K
How far from its usual level
+28.4
Same report last year
1.7M
History used
2,159 days
the 28 Jun 2024 report24 earlier reportsnormal: 2.0M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 7.2M shares sold short in the 14 Jun 2024 report, 3.2× the same report last year.
Same report last year: 2.2M; its normal report is 2.0M.
See the evidence
This period
7.2M (the 14 Jun 2024 report)
Normal report (median of 24 earlier)
2.0M
Typical spread (median absolute deviation)
123K
How far from its usual level
+26.1
Same report last year
2.2M
History used
2,145 days
the 14 Jun 2024 report24 earlier reportsnormal: 2.0M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 6.7M shares sold short in the 31 May 2024 report, 3.4× the same report last year.
Same report last year: 2.0M; its normal report is 2.0M.
See the evidence
This period
6.7M (the 31 May 2024 report)
Normal report (median of 24 earlier)
2.0M
Typical spread (median absolute deviation)
96K
How far from its usual level
+24.0
Same report last year
2.0M
History used
2,131 days
the 31 May 2024 report24 earlier reportsnormal: 2.0M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 6.2M shares sold short in the 15 May 2024 report, 3.2× the same report last year.
Same report last year: 1.9M; its normal report is 2.0M.
See the evidence
This period
6.2M (the 15 May 2024 report)
Normal report (median of 24 earlier)
2.0M
Typical spread (median absolute deviation)
90K
How far from its usual level
+21.6
Same report last year
1.9M
History used
2,115 days
the 15 May 2024 report24 earlier reportsnormal: 2.0M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
saw 47 13F filers open a new position in the quarter ended 31 Mar 2024, 9.4× the same quarter last year; it also reported revenue of $20.1M for the quarter ended 30 Jun 2024, 1.5× the same quarter last year; and it had 11.1M shares sold short in the 30 Sep 2024 report, 5.4× the same report last year. Three unrelated kinds of activity within 182 days.
See the evidence (15 changes)
Short interest and volume: Short interest spike became public on 25 Apr 2024
Aquestive Therapeutics had 4.0M shares sold short in the 15 Apr 2024 report, 2.1× the same report last year.
This period
4.0M (the 15 Apr 2024 report)
Normal report (median of 24 earlier)
1.9M
Typical spread (median absolute deviation)
92K
How far from its usual level
+10.6
Same report last year
1.9M
History used
2,085 days
the 15 Apr 2024 report24 earlier reportsnormal: 1.9M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 10 May 2024
Aquestive Therapeutics had 5.3M shares sold short in the 30 Apr 2024 report, 2.9× the same report last year.
This period
5.3M (the 30 Apr 2024 report)
Normal report (median of 24 earlier)
2.0M
Typical spread (median absolute deviation)
95K
How far from its usual level
+17.0
Same report last year
1.8M
History used
2,100 days
the 30 Apr 2024 report24 earlier reportsnormal: 2.0M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Institutional holdings: Many funds opening a new position became public on 15 May 2024
Aquestive Therapeutics saw 47 13F filers open a new position in the quarter ended 31 Mar 2024, 9.4× the same quarter last year.
This period
47 (the quarter ended 31 Mar 2024)
Normal quarter (median of 8 earlier)
5
Typical spread (median absolute deviation)
2
How far from its usual level
+14.0
Same quarter last year
5
History used
2,009 days
the quarter ended 31 Mar 20248 earlier quartersnormal: 5
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
Short interest and volume: Short interest spike became public on 25 May 2024
Aquestive Therapeutics had 6.2M shares sold short in the 15 May 2024 report, 3.2× the same report last year.
This period
6.2M (the 15 May 2024 report)
Normal report (median of 24 earlier)
2.0M
Typical spread (median absolute deviation)
90K
How far from its usual level
+21.6
Same report last year
1.9M
History used
2,115 days
the 15 May 2024 report24 earlier reportsnormal: 2.0M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 12 Jun 2024
Aquestive Therapeutics had 6.7M shares sold short in the 31 May 2024 report, 3.4× the same report last year.
This period
6.7M (the 31 May 2024 report)
Normal report (median of 24 earlier)
2.0M
Typical spread (median absolute deviation)
96K
How far from its usual level
+24.0
Same report last year
2.0M
History used
2,131 days
the 31 May 2024 report24 earlier reportsnormal: 2.0M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 27 Jun 2024
Aquestive Therapeutics had 7.2M shares sold short in the 14 Jun 2024 report, 3.2× the same report last year.
This period
7.2M (the 14 Jun 2024 report)
Normal report (median of 24 earlier)
2.0M
Typical spread (median absolute deviation)
123K
How far from its usual level
+26.1
Same report last year
2.2M
History used
2,145 days
the 14 Jun 2024 report24 earlier reportsnormal: 2.0M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 11 Jul 2024
Aquestive Therapeutics had 7.6M shares sold short in the 28 Jun 2024 report, 4.4× the same report last year.
This period
7.6M (the 28 Jun 2024 report)
Normal report (median of 24 earlier)
2.0M
Typical spread (median absolute deviation)
123K
How far from its usual level
+28.4
Same report last year
1.7M
History used
2,159 days
the 28 Jun 2024 report24 earlier reportsnormal: 2.0M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 25 Jul 2024
Aquestive Therapeutics had 10.4M shares sold short in the 15 Jul 2024 report, 5.4× the same report last year.
This period
10.4M (the 15 Jul 2024 report)
Normal report (median of 24 earlier)
2.0M
Typical spread (median absolute deviation)
147K
How far from its usual level
+38.3
Same report last year
1.9M
History used
2,176 days
the 15 Jul 2024 report24 earlier reportsnormal: 2.0M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Financials: Quarterly revenue change became public on 13 Aug 2024
Aquestive Therapeutics reported revenue of $20.1M for the quarter ended 30 Jun 2024, 1.5× the same quarter last year.
This period
$20.1M (the quarter ended 30 Jun 2024)
Normal quarter (median of 8 earlier)
$12.5M
Typical spread (median absolute deviation)
$726K
How far from its usual level
+6.0
Same quarter last year
$13.2M
History used
2,648 days
the quarter ended 30 Jun 20248 earlier quartersnormal: $12.5M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
Short interest and volume: Short interest spike became public on 10 Aug 2024
Aquestive Therapeutics had 10.8M shares sold short in the 31 Jul 2024 report, 5.3× the same report last year.
This period
10.8M (the 31 Jul 2024 report)
Normal report (median of 24 earlier)
2.0M
Typical spread (median absolute deviation)
205K
How far from its usual level
+28.8
Same report last year
2.0M
History used
2,192 days
the 31 Jul 2024 report24 earlier reportsnormal: 2.0M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 27 Aug 2024
Aquestive Therapeutics had 10.8M shares sold short in the 15 Aug 2024 report, 5.5× the same report last year.
This period
10.8M (the 15 Aug 2024 report)
Normal report (median of 24 earlier)
2.0M
Typical spread (median absolute deviation)
226K
How far from its usual level
+26.1
Same report last year
2.0M
History used
2,207 days
the 15 Aug 2024 report24 earlier reportsnormal: 2.0M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 12 Sep 2024
Aquestive Therapeutics had 10.8M shares sold short in the 30 Aug 2024 report, 5.9× the same report last year.
This period
10.8M (the 30 Aug 2024 report)
Normal report (median of 24 earlier)
2.1M
Typical spread (median absolute deviation)
244K
How far from its usual level
+24.2
Same report last year
1.8M
History used
2,222 days
the 30 Aug 2024 report24 earlier reportsnormal: 2.1M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 25 Sep 2024
Aquestive Therapeutics had 10.8M shares sold short in the 13 Sep 2024 report, 5.8× the same report last year.
This period
10.8M (the 13 Sep 2024 report)
Normal report (median of 24 earlier)
2.2M
Typical spread (median absolute deviation)
340K
How far from its usual level
+17.1
Same report last year
1.8M
History used
2,236 days
the 13 Sep 2024 report24 earlier reportsnormal: 2.2M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 10 Oct 2024
Aquestive Therapeutics had 11.1M shares sold short in the 30 Sep 2024 report, 5.4× the same report last year.
This period
11.1M (the 30 Sep 2024 report)
Normal report (median of 24 earlier)
2.3M
Typical spread (median absolute deviation)
520K
How far from its usual level
+11.4
Same report last year
2.0M
History used
2,253 days
the 30 Sep 2024 report24 earlier reportsnormal: 2.3M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 25 Oct 2024
Aquestive Therapeutics had 10.8M shares sold short in the 15 Oct 2024 report, 5.4× the same report last year.
This period
10.8M (the 15 Oct 2024 report)
Normal report (median of 24 earlier)
3.2M
Typical spread (median absolute deviation)
1.4M
How far from its usual level
+3.7
Same report last year
2.0M
History used
2,268 days
the 15 Oct 2024 report24 earlier reportsnormal: 3.2M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
15 May 2024Institutional holdings change
saw 47 13F filers open a new position in the quarter ended 31 Mar 2024, 9.4× the same quarter last year.
Same quarter last year: 5; its normal quarter is 5.
See the evidence
This period
47 (the quarter ended 31 Mar 2024)
Normal quarter (median of 8 earlier)
5
Typical spread (median absolute deviation)
2
How far from its usual level
+14.0
Same quarter last year
5
History used
2,009 days
the quarter ended 31 Mar 20248 earlier quartersnormal: 5
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
had 5.3M shares sold short in the 30 Apr 2024 report, 2.9× the same report last year.
Same report last year: 1.8M; its normal report is 2.0M.
See the evidence
This period
5.3M (the 30 Apr 2024 report)
Normal report (median of 24 earlier)
2.0M
Typical spread (median absolute deviation)
95K
How far from its usual level
+17.0
Same report last year
1.8M
History used
2,100 days
the 30 Apr 2024 report24 earlier reportsnormal: 2.0M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 4.0M shares sold short in the 15 Apr 2024 report, 2.1× the same report last year.
Same report last year: 1.9M; its normal report is 1.9M.
See the evidence
This period
4.0M (the 15 Apr 2024 report)
Normal report (median of 24 earlier)
1.9M
Typical spread (median absolute deviation)
92K
How far from its usual level
+10.6
Same report last year
1.9M
History used
2,085 days
the 15 Apr 2024 report24 earlier reportsnormal: 1.9M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Fires on an 8-K with item 5.02 after 90 days without one.
Showing the newest 40 of 108 entries; narrow the window or the kind of data to see older ones.
Not listed: 201 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.
Identifiers and sources
How records are matched to this company, and what each source holds for it
Cik
0001398733
Ticker
AQST
Domain
aquestive.com
Hq location
NJ|WARREN| (1 unverified)
Lobbying client
aquestive therapeutics
Name
Aquestive Therapeutics, Inc., MonoSol Rx, Inc.
Uei
XBKKRRJPR255
Federal lobbying disclosures (LDA)5 records, 71 data points20 May 2019 to 30 Sep 2026
SEC Form 13F institutional holdings297 data points30 Sep 2018 to 30 Sep 2026
SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)188 records9 May 2018 to 3 Nov 2026
SEC XBRL company facts (revenue, capex, R&D, backlog...)645 data points31 Dec 2016 to 30 Oct 2026
SEC Form 4 insider transactions61 records, 160 data points26 Jul 2018 to 16 Nov 2026
FINRA short interest (twice monthly)593 data points31 Jul 2018 to 30 Oct 2026
FINRA daily short sale volume (off-exchange)4178 data points1 Aug 2018 to 20 Nov 2026